Oncology

Finding a cure for pancreatic cancer, which is among the deadliest cancers, will require both systemic therapy and local therapy, researchers said.

A new study shows a lack of racial and ethnic diversity in clinical trials for cancer drugs, highlighting issues currently being addressed by the FDA.

Lani M. Alison, BSN, MS, HCQ, PCMH, CCE, vice president of Clinical Affairs, Regional Cancer Care Associates, discusses how providers discuss the Oncology Care Model (OCM) with patients and the questions they ask about it.

AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.

Chronic pain, obesity and cancer, multiple myeloma patterns, pancreatic cancer screening updates, and more.

Coverage from the National Comprehensive Cancer Network Policy Summit held June 27, 2019, in Washington, DC.

The fault, dear Brutus, is not in our stars, but in ourselves... Julius Caesar (I, ii, 140-141)

Scientists uncovered a rare, inherited gene mutation, known as RABL3, that raises the risk of pancreatic and other cancers.

The founder of Oneinforty discusses the importance of identifying populations at high risk of hereditary cancers, as well as the need for education, testing, and other steps to prevent cancer.

The Institute for Value-Based Medicine®, an initiative of The American Journal of Managed Care®, traveled to Teaneck, New Jersey, for presentations in partnership with Regional Cancer Care Associates.

A 28% reduction in hospital admissions leads to a broader agreement, the physicians' group and payer say.

A review of the documentary on the life of James P. Allison, PhD, of The University of Texas MD Anderson Cancer Center, co-winner of the 2018 Nobel Prize in Physiology or Medicine.

On this episode of Managed Care Cast, we’re bringing you a portion of a panel discussion about the Oncology Care Model, held in July 2019 during a meeting of The Institute for Value-Based Medicine® (IVBM), an initiative of The American Journal of Managed Care®. At IVBM events, we gather thought leaders to share best practices across medicine, pharmacy, and management in regional locations around the country. This podcast is taken from our meeting focusing on Innovation and Quality in Oncology Care.

As survival rates for malignant melanoma increase, so does the likelihood that some patients will develop second primary cancers.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Weeks after the first 2 anticancer biosimilars entered the US market, OneOncology announced that its partner practices have already started administering the drugs.

Innovation is being used to improve quality metrics in oncology care at the patient forefront and in data, explained Lani M. Alison, BSN, MS, HCQ, PCMH, CCE, vice president of Clinical Affairs, Regional Cancer Care Associates.

A single-dose human papillomavirus (HPV) vaccination strategy could be effective in less developed countries, where cost is in consideration.

High costs of care, particularly for prescription drugs, dominated a discussion of cancer care at the state level during the June 27, 2019, National Comprehensive Cancer Network Policy Summit in Washington, DC.

The study found that the advantage was due to factors that affect hospital safety, which were present before affiliation and increased afterward.

Nivolumab (Opdivo) monotherapy is currently indicated for the treatment of patients with hepatocellular carcinoma who were previously treated with the targeted therapy sorafenib, sold as Nexavar, based on the CheckMate 040 trial. Assessing the safety and efficacy of nivolumab in combination with ipilimumab (Yervoy) among these patients, researchers have observed clinically meaningful responses and an acceptable safety profile.

Researchers from Houston Methodist Cancer Center and The University of Texas MD Anderson Cancer Center said they demonstrated a new monoclonal antibody blocked ovarian and pancreatic tumor activity in mice.

When it comes to performing high-risk procedures, the majority of hospitals do not perform them often enough to meet safety standards, according to a new report from The Leapfrog Group.

A phase 2b clinical trial is producing promising results for a personalized cancer vaccine used in patients with stage III and IV resected melanoma.